Company Profiles

driven by the PitchBook Platform

Apitope International

Description

Provider of antigen-specific therapeutic peptides designed to develop novel therapeutics that directly target the underlying cause of allergy and autoimmune disease. The company's peptide therapies are focused pm the treatment of allergy and autoimmune diseases, including multiple sclerosis, Graves' disease and Uveitis, enabling patients to enjoy a normal quality of life without the risk of secondary infection and further complications.

2002

Founded

PRIVATE

Status

1-10

Employees

Series B

Latest Deal Type

$13.5M

Latest Deal Amount

$26.8M

Total Amount Raised

Description

Provider of antigen-specific therapeutic peptides designed to develop novel therapeutics that directly target the underlying cause of allergy and autoimmune disease. The company's peptide therapies are focused pm the treatment of allergy and autoimmune diseases, including multiple sclerosis, Graves' disease and Uveitis, enabling patients to enjoy a normal quality of life without the risk of secondary infection and further complications.

Website:

www.apitope.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

Agoralaan Building A-bis 3590 DiepenbeekBelgium +32 (0)1 128 69 00
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Apitope International's full profile, request a free trial.

    Apitope International Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Apitope International Investors (9)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Arthurian Life SciencesAsset ManagerMinority000 0000000 0000
    LRMVenture CapitalMinority000 0000000 0000
    National Multiple Sclerosis Society (NMSS)OtherMinority000 0000000 0000
    ParticipatieMaatschappij VlaanderenVenture CapitalMinority000 0000000 0000
    University of BristolCorporationMinority000 0000000 0000
    Arthurian Life Sciences Asset Manager
    LRM Venture Capital
    National Multiple Sclerosis Society (NMSS) Other
    ParticipatieMaatschappij Vlaanderen Venture Capital
    University of Bristol Corporation

    Apitope International Executive Team (7)

    NameTitleBoard
    Seat
    Contact
    Info
    Keith Martin Ph.DChief Executive Officer & Board Member
    David WraithFounder, Chief Scientific Officer & Board Member
    Hayley French Ph.DCommercial Director & General Counsel
    Graham Roberts Ph.DDirector, Development
    Andrea Jahraus Ph.DDirector, Operations
    Keith Martin Ph.D Chief Executive Officer & Board Member
    David Wraith Founder, Chief Scientific Officer & Board Member
    Hayley French Ph.D Commercial Director & General Counsel
    Graham Roberts Ph.D Director, Development
    Andrea Jahraus Ph.D Director, Operations

    Apitope International Board Members (6)

    NameRepresentingRoleSinceContact
    Info
    Barbara Leyman Ph.DLRMHead of Health & Care000 0000
    Brenig PreestArthurian Life SciencesInvestment Director000 0000
    Gaston Matthyssens Ph.DVesalius Biocapital PartnersManaging Partner000 0000
    Keith Martin Ph.DApitope InternationalChief Executive Officer & Board Member000 0000
    Richard DanielsSelfBoard Member000 0000
    Barbara Leyman Ph.D Head of Health & Care LRM
    Brenig Preest Investment Director Arthurian Life Sciences
    Gaston Matthyssens Ph.D Managing Partner Vesalius Biocapital Partners
    Keith Martin Ph.D Chief Executive Officer & Board Member Apitope International
    Richard Daniels Board Member Self
    Request full access to PitchBook